REG - Creo Medical Group - First robotic-guided lung ablation cases commence

Creo MedicalAnnouncement

15/01/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250115:nRSO3349Ta&default-theme=true

RNS Number : 3349T  Creo Medical Group PLC  15 January 2025

Creo Medical Group plc

("Creo" the "Company" or the "Group")

 

First robotic-guided lung ablation cases commence

as part of Intuitive collaboration agreement

 

Robotic-guided microwave ablation of cancerous lung tissue now being
undertaken at two UK sites

 

Creo Medical Group plc (AIM: CREO), a medical device company focused on the
emerging field of minimally invasive surgical endoscopy for pre-cancer and
cancer patients, announces that the first robotic-guided microwave ablation of
cancerous lung tissue cases have commenced at a leading UK hospital (the
"Hospital").

 

As announced in July 2024
(https://www.londonstockexchange.com/news-article/CREO/creo-and-intuitive-amend-collaboration-agreement/16547222)
, the Company amended its multi-year collaboration with Intuitive and this
latest robotic-guided microwave ablation procedure for lung cancer is the
first clinical case using Intuitive's Ion Endoluminal System and Creo's
MicroBlate™ Flex ablation device to take place under the amended terms of
the agreement at the Hospital.

 

The Hospital is now the second site to have performed microwave ablation
procedures for lung cancer. The first UK site to perform such procedures was
the Royal Brompton Hospital as part of an ongoing clinical study(1) conducted
by Professor Shah.

 

The Pioneer Programme will continue to roll-out throughout 2025 to support the
collection of clinical evidence ahead of the sites entering a commercial
phase, and the Company expects the number of procedures performed to grow in
the current year.

 

Craig Gulliford, Chief Executive Officer of Creo, said: "We are delighted that
this first clinical site under the Pioneer Programme, representing a second UK
clinical site, has started clinical practice and successfully completed their
first robotic-guided lung cancer ablation procedure using Creo's MicroBlate
Flex alongside Intuitive's Ion Endoluminal System. With both the clinical
study at the Royal Brompton and this site as part of the clinical Pioneer
Programme, we now have two UK hospitals undertaking these procedures. These
sites, under the amended collaboration agreement with Intuitive, will provide
us with the clinical evidence needed to support the wider commercialisation of
the MicroBlate Flex device. We look forward to updating shareholders on our
progress."

 

(1) Bronchoscopic Microwave Ablation of Lung Tissue - Full Text View -
ClinicalTrials.gov
(https://protect.checkpoint.com/v2/___https:/urldefense.proofpoint.com/v2/url?u=https-3A__clinicaltrials.gov_ct2_show_NCT05786625&d=DwMGaQ&c=euGZstcaTDllvimEN8b7jXrwqOf-v5A_CdpgnVfiiMM&r=WovxkIrimZbJDsUY12yOjDzcN9uTu1TmGAhgw0TiZCY&m=OyslDpKJqy5cCdxpsKvu7ObhyVN8HFcoqPf4POVajZw&s=Nhy0JhSAmWouYJ4rmkuq8b9i6Y0LIMMiSO07LToAjiw&e=___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6Njo0NWJiOmVkMjQxYTEwOWU4MjYxNGE2MWUzNzlhMjhiOTgxMWNhNGUzNjE0MTYzZWM3ZGIwM2ZiZjI4Y2YwNzZhMTMxOTA6cDpUOk4)

 

 For further information please contact:

 

 Creo Medical Group plc                                                  www.creomedical.com
                                                                         (https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)
 Richard Craven, Company Secretary                                       Via Walbrook PR

 Cavendish Capital Markets Limited

 (Nominated Adviser and Joint Broker)                                    +44 (0)20 7220 0500
 Stephen Keys / Camilla Hume / George Lawson (NOMAD)
 Michael Johnson (Sales)

 Deutsche Numis (Joint Broker)                                           +44 (0)20 7260 1000

 Freddie Barnfield / Duncan Monteith / Euan Brown

 Walbrook PR Ltd                Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com (mailto:creo@walbrookpr.com)
 Paul McManus / Alice Woodings  Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 Phillip Marriage               Mob: +44 (0)7867 984 082

 

 

About Creo Medical

Creo is a medical device company focused on the development and
commercialisation of minimally invasive electrosurgical devices, bringing
advanced energy to endoscopy.

 

The Company's vision is to improve patient outcomes through the development
and commercialisation of a suite of electrosurgical medical devices, each
enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA
powered by Kamaptive full-spectrum adaptive technology to optimise surgical
capability and patient outcomes. Kamaptive is a seamless, intuitive
integration of multi-modal energy sources, optimised to dynamically adapt to
patient tissue during procedures such as resection, dissection, coagulation,
and ablation of tissue. Kamaptive technology provides clinicians with
increased flexibility, precision and controlled surgical solutions. CROMA
currently delivers bipolar radiofrequency ("RF") energy for precise localised
cutting and focused high frequency microwave ("MW") energy for controlled
coagulation and ablation via a single accessory port. This technology,
combined with the Group's range of patented electrosurgical devices, is
designed to provide clinicians with flexible, accurate and controlled clinical
solutions. The Directors believe the Company's technology can impact the
landscape of surgery and endoscopy by providing a safer, less invasive and
more cost-efficient option for procedures.

 

For more information, please refer to the website www.creomedical.com
(https://protect.checkpoint.com/v2/___http:/www.creomedical.com/___.YzJ1OmludHVpdGl2ZTpjOm86NWJlYzBmMzJjY2MyZTBiZWFkNmJkZmVmNzdhM2MwMTI6NjoyYWU4OjczNzQyNWUwODBjYTEwNzAxYWMzNWEyZDQ3YzI1ZmEwYWMzYTc4M2Q2M2NjYzEyNTQwZWM3ODc4NTk3NTE4YTQ6cDpUOk4)

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGPUPCGUPAPUC